Myrexis, Inc. Reports Azixa(R) Phase 2 Study Results at 2011 American Society of Clinical Oncology Annual Meeting

SALT LAKE CITY, June 6, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced presentation of Phase 2 clinical study results from its lead product candidate Azixa (verubulin) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2011, in Chicago, IL. The Phase 2 results are from the Company's open-label Azixa monotherapy study in patients with recurrent glioblastoma multiforme (GBM) who had failed prior standard of care chemotherapy, but who are naïve to Avastin®(bevacizumab).